Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of Baxter International Inc. shareholders who purchased stock between February 23, 2022, and July 30, 2025, alleging that the company misled investors regarding the safety and efficacy of its Novum LVP devices [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP devices, which led to malfunctions and posed serious risks to patients [5]. - Allegations include that Baxter was aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [5]. - The lawsuit asserts that Baxter's statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Participation Information - Shareholders who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [2][3]. Allegations - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period†). Baxter develops, manufactures, and markets medical products. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen. ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to systemic defects in its Novum IQ Large Volume Pump, which posed serious risks to patients [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter made false or misleading statements regarding the Novum IQ Large Volume Pump, which suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - The company announced on July 31, 2025, a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Points - Baxter International Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to a federal securities class action [1] - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action against Baxter [1] Company Overview - Baxter International Inc. is listed on the NYSE under the ticker symbol BAX [1] - Faruqi & Faruqi, LLP is a national securities law firm with offices in New York, Pennsylvania, California, and Georgia [1]

Core Viewpoint - A securities class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered from systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of all individuals or entities that purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter failed to disclose significant issues with the Novum LVP, including systemic defects that caused malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [2]. Group 2: Implications for Baxter - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might have to halt all new sales of these pumps [2]. - The statements made by Baxter regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 3: Investor Actions - Investors who acquired shares of Baxter are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 15, 2025 [3].

LOS ANGELES--(BUSINESS WIRE)---- $BAX--BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against Baxter International, Inc. and certain executives, alleging misleading statements regarding the safety and efficacy of the Novum IQ Large Volume Pump, which has been linked to serious patient risks [1][2][4]. Company Overview - Baxter International, Inc. is a global healthcare company that develops and sells medical products for hospitals and healthcare facilities. The company recently launched the Novum IQ Large Volume Pump, which is intended for intravenous fluid delivery [2]. Allegations in the Lawsuit - The lawsuit claims that Baxter and its executives misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not adequately address these issues [2]. - The lawsuit also states that Baxter's communications regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Timeline of Events - Safety concerns regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion issues. Baxter issued warning letters to customers about potential risks shortly thereafter [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in the company's stock price [4]. Class Action Details - Individuals who purchased Baxter common stock during the specified class period may seek appointment as Lead Plaintiff in the lawsuit, with a deadline for filing motions set for December 15, 2025 [5].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Opportunity - Wall Street is investing heavily in AI, but there is a looming energy crisis as AI technologies require vast amounts of electricity, comparable to the consumption of small cities [2][3] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI data centers, making it a potentially lucrative investment [3][8] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses significant nuclear energy infrastructure assets, which are crucial for America's future power strategy, and is capable of executing large-scale engineering projects across various energy sectors [7][8] Financial Health - The company is noted for being debt-free and having a substantial cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] - It also holds a significant equity stake in another AI-related company, providing indirect exposure to multiple growth opportunities in the AI sector [9][10] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off the radar, trading at less than seven times earnings excluding cash and investments [9][10] - The company is recognized for delivering real cash flows and owning critical infrastructure, making it a compelling investment choice in the context of the AI and energy sectors [11][12]

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of Baxter International Inc. (NYSE: BAX ) have been seeing fresh flows as the business continues to struggle. In April, I believed that the situation was messy, yet appealing, if only manag ...